Drug intelligence / Profile preview

Fexofast

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

Fexofast is a second-generation antihistamine developed and marketed by Eurodrug. Its active ingredient is fexofenadine hydrochloride, which acts as a selective peripheral Histamine H1 receptor antagonist. The drug is indicated for the treatment of allergic conditions, specifically allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). As a non-sedating small molecule, Fexofast provides rapid and sustained relief from allergic symptoms without readily crossing the blood-brain barrier. It is typically available in tablet formulations, such as Fexofast-180, and is designed for once-daily dosing to improve patient compliance.

Brand names: FexofastFexofast-180Fexofast180Fexofast 180FexofinGebenir
Other names: fexofenadine hydrochloridefexofenadine HCl

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Fexofast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fexofast.

Explore the full profile